Ribo Biopharma and Madrigal Achieve First Key Milestone in MASH siRNA Collaboration, Accelerating Joint Development

July 2, 2026, Suzhou, China · Mölndal, Sweden —Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals(collectively referred to as "Ribo Life Science") andMadrigal Pharmaceuticals, Inc.(Nasdaq: MDGL, hereinafter referred to as “Madrigal”) jointly announced that, through an efficient collaboration mechanism,The jointly developed siRNA project by both parties has successfully selected the first candidate drug molecule, marking the successful achievement of the first key milestone and paving the way for the initiation of preclinical studies, thereby laying a solid foundation for subsequent clinical development.

This collaboration fully demonstratesRibo Life Science and Madrigal’s Unwavering Commitment to Advancing Innovative siRNA Therapies for Liver DiseasesThe collaboration primarily focuses on metabolic dysfunction-associated steatohepatitis (MASH), a condition with significant unmet medical needs and an urgent demand for the development of superior therapeutic options. Leveraging Ribo Life Science’s multiple preclinical assets, both parties will combine their respective strengths in the field of liver diseases to further broaden the future therapeutic landscape for MASH.

Dr. Li-Ming Gan, Co-CEO and President of Global R&D at Ribo Life Science“He stated, ‘We are delighted to have achieved the first key milestone with Madrigal within just five months. Madrigal’s global market leadership and clinical development capabilities in the MASH field are widely recognized, while Ribo Life Science, as a leading pioneer in oligonucleotide therapeutics, boasts best-in-class siRNA drug discovery and delivery technologies. The synergy between the two parties is driving the project forward at an accelerated pace. We look forward to collaborating with Madrigal to continuously expedite the co-development of siRNA therapeutics, aiming to bring revolutionary oligonucleotide treatment options to MASH patients worldwide as soon as possible.’”